Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II/III breast cancer: Results from the adaptively randomized I-SPY2 trial
Lajos Pusztai(Yale University), Laura J. Esserman(University of California, San Francisco), Rita Nanda(University of Chicago), Angela DeMichele(University of Pennsylvania), Denise M. Wolf, Richard B. Schwab(Center for Personalized Cancer Treatment), Andres Forero‐Torres(Kirklin Clinic), Alexandra Thomas(Cliniques Universitaires Saint-Luc), Adam L. Asare(Quantum Leap Healthcare Collaborative), Scott Berry(Queen's University), Lamorna Brown Swigart(University of California, San Francisco), Amy Wilson(Quantum Leap Healthcare Collaborative), Minetta C. Liu(Mayo Clinic), Julia Wulfkuhle(University of California, San Francisco), Ruby Singhrao(University of California, San Francisco), Judy C. Boughey(Mayo Clinic in Arizona), Douglas Yee(University of Minnesota Medical Center), Nola M. Hylton(University of California, San Francisco), Laura Sit(Memorial Sloan Kettering Cancer Center), Smita Asare(Quantum Leap Healthcare Collaborative), Rebecca Shatsky(University of California San Diego), A. Jo Chien(University of California, San Francisco), Kevin Kalinsky(Emory University), Hyo S. Han(Moffitt Cancer Center), Kathy S. Albain(Loyola University Chicago), Christina Yau(Hospital Authority), Amy S. Clark(Abramson Center for Jewish Life), Jeffrey B. Matthews(University of California, San Francisco), Kathleen Kemmer(University of Michigan), Claudine Isaacs(Georgetown University), Jane Perlmutter(Gemini Computers (United States)), Donald A. Berry(Berry & Associates (United States)), Gillian L. Hirst(University of California, San Francisco), Lili Du(The University of Texas MD Anderson Cancer Center), Hope S. Rugo(City of Hope), Anne M. Wallace(University of California San Diego), Anthony Elias(University of Colorado Cancer Center), Heather Beckwith(University of Minnesota Medical Center), Ashish Sanil(Berry & Associates (United States)), Erica String-Reasor(University of Alabama at Birmingham), Laura J. van’t Veer(University of California, San Francisco), Theresa L. Helsten(University of California San Diego), Michelle Melisko(University of California, San Francisco), Emmanuel Petricoin(George Mason University), W. Fraser Symmans(The University of Texas MD Anderson Cancer Center)
Cited by 330
Related Papers
The Immune Landscape of Cancer
|Immunity|2018|6.2k
Pembrolizumab for Early Triple-Negative Breast Cancer
|New England Journal of Medicine|2020|3.1k
Palbociclib and Letrozole in Advanced Breast Cancer
|New England Journal of Medicine|2016|2.9k
Symptom Monitoring With Patient-Reported Outcomes During Routine Cancer Treatment: A Randomized Controlled Trial
|Journal of Clinical Oncology|2015|2.6k
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
|New England Journal of Medicine|2022|2.5k